Merck & Co. and Sanofi have developed agreements with Natrix Separations, a Burlington, Ontario-based supplier of single-use and multi-cycle disposable chromatography products, to advance Natrix’s membrane-based Protein A technology platform for antibody purification.

The Natrix Protein A platform is being applied for antibody purification in single-use-based biologics production facilities for both batch and continuous processes.

Under the agreements, investments by Merck and Sanofi, along with technology collaboration between the individual collaborators and Natrix, will accelerate Natrix’s platform commercialization program. Specific financial terms were not disclosed.

Separately, Natrix has entered into an agreement with Scil Proteins, a Halle (Saale), Germany-based protein-engineering company, for the engineering and development of the proprietary Protein A ligand that will be integrated with Natrix’s membrane technology.

Source: Natrix Separations